Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BofA Securities on argenx SE (ARGX): '2026 remains a catalyst-rich year'
December 15, 2025 10:24 AM ESTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $942.00 price target on argenx SE (NASDAQ: ARGX)
The analyst comments "Argenx (ARGX) announced the phase 3 UplighTED studies evaluating efgartigimod in thyroid eye disease (TED) will be discontinued following a pre-specified futility analysis. Management highlighted... More
argenx discontinues thyroid eye disease studies after futility analysis
December 15, 2025 6:56 AM ESTargenx SE (Euronext & Nasdaq: ARGX) announced it will discontinue its Phase 3 UplighTED studies evaluating efgartigimod subcutaneous in adults with moderate to severe thyroid eye disease.
The decision follows a recommendation from an Independent Data Monitoring Committee to stop the trials for futility after reviewing data from a pre-specified interim... More
argenx SE (ARGX) PT Raised to $1,248 at Stifel: Vyvgart Dominates MG Market
December 11, 2025 6:54 AM ESTStifel analyst Alex Thompson raised the price target on argenx SE (NASDAQ: ARGX) to $1,248.00 (from $1,028.00) while maintaining a Buy rating.
The analyst commented, "Vyvgart continues to dominate the MG market as the #1 prescribed biologic in the space while growing faster... More
argenx SE (ARGX) PT Raised to $1,316 at Wells Fargo
December 11, 2025 6:25 AM ESTWells Fargo analyst Yanan Zhu raised the price target on argenx SE (NASDAQ: ARGX) to $1,316.00 (from $1,095.00) while maintaining a Overweight rating.... More
